Corrigendum to: Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion (Clin Ophthalmol, (2017) 11, (403-408), 10.2147/OPTH.S128651);Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion

Clinical Ophthalmology

Volumn 11, Issue , 2017, Pages 403-408

  Tagami, Mizuki ^a   Sai, Ryuto ^a   Fukuda, Masahide ^a   Azumi, Atsushi ^a  

^a KOBE KAISEI HOSPITAL   (Japan)

Author keywords

Aflibercept; Branch retinal vein occlusion; Macular edema; Ranibizumab

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB;

AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG SAFETY; EYE DISEASE; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); MACULAR EDEMA; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SUBSTITUTION THERAPY; SYSTEMIC DISEASE; TREATMENT DURATION; VISUAL ACUITY;

EID: 85013742294     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S136670     Document Type: Erratum

References (25)

1. Yasuda M, Kiyohara Y, Arakawa S, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci. 2010;51(6):3205–3209.
2. Wang JK, Huang TL, Su PY, Chang PY, Tseng YY. Intravitreal aflibercept for macular edema secondary to branch retinal vein occlusion in Chinese patients. Eye Sci. 2015;30(2):63–66.
3. Wang JK, Su PY, Hsu YR, Chen YJ, Chen FT, Tseng YY. Comparison of the efficacy of intravitreal aflibercept and bevacizumab for macular edema secondary to branch retinal vein occlusion. J Ophthalmol. 2016; 2016:8421940.
4. Saishin Y, Ito Y, Fujikawa M, Sawada T, Ohji M. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion. Jpn J Ophthalmol. Epub 2016 Sep 22.
5. Wirth MA, Becker MD, Graf N, Michels S. Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab – a pilot study. Int J Retin Vitr. 2016;2:20.
6. Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. Klin Monbl Augenheilkd. 2015;232(4):552–555.
7. Eadie JA, Ip MS, Kulkarni AD. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina. 2014;34(12):2439–2443.
8. Cohen MN, Houston SK, Juhn A, et al. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. Can J Ophthalmol. 2016;51(5):342–347.
9. Pfau M, Fassnacht-Riederle H, Becker MD, Graf N, Michels S. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Ophthalmic Res. 2015; 54(3):150–156.
10. Papakostas TD, Lim L, van Zyl T, et al. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye (Lond). 2016;30(1):79–84.
11. Tagami M, Kusuhara S, Imai H, Honda S, Tsukahara Y, Negi A. Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion. Ophthalmologica. 2011;226(2):81–86.
12. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6): 1102–1112.
13. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6): 1124–1133.
14. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–809.
15. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3): 538–544.
16. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024–1032.
17. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278–284.
18. Capone A Jr, Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina. 2014;34(2):342–351.
19. Pichi F, Specchia C, Vitale L, et al. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. Am J Ophthalmol. 2014;157(3):607–615.
20. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2): 171–185.
21. Park SJ, Choi Y, Na YM, et al. Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model. Invest Ophthalmol Vis Sci. 2016;57(6):2612–2617.
22. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Reports. 2011;1:e5.
23. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667–668.
24. Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. Epub 2016 Feb 17.
25. Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M. Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci. 2015;56(11):6501–6505.